The peptide landscape for metabolic research has undergone a revolution in the past five years. What began with first-generation GLP-1 receptor agonists has expanded into a multi-target approach that addresses appetite regulation, insulin sensitivity, lipid metabolism, and direct fat cell signaling. This article reviews the most clinically relevant peptides for weight loss research, their mechanisms of action, and what the current evidence shows.
GLP-1 Receptor Agonists: The Foundation
Glucagon-like peptide-1 (GLP-1) receptor agonists work by mimicking the endogenous GLP-1 hormone, which is secreted by intestinal L-cells in response to food intake. GLP-1 stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and — critically for weight loss — acts on hypothalamic receptors to reduce appetite and increase satiety. The result is a significant reduction in caloric intake without the metabolic suppression seen with traditional caloric restriction.
| Peptide | Receptor Targets | Avg. Weight Loss (Research) | Half-Life | Administration |
|---|---|---|---|---|
| Semaglutide | GLP-1R | ~15% body weight | ~7 days | Weekly SubQ |
| Tirzepatide | GLP-1R + GIPR | ~20–22% body weight | ~5 days | Weekly SubQ |
| Retatrutide | GLP-1R + GIPR + GCGR | ~24% body weight | ~6 days | Weekly SubQ |
| AOD-9604 | β3-AR (fat cells) | Moderate, localized | ~30 min | Daily SubQ |
| 5-Amino-1MQ | NNMT inhibitor | Moderate, metabolic | ~4–6 hours | Oral |
Semaglutide: The Benchmark
Semaglutide (the active ingredient in Ozempic and Wegovy) established the modern benchmark for peptide-based weight loss. In the STEP trials, participants receiving 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks — more than double the efficacy of any prior pharmacological intervention. Its once-weekly dosing and well-characterized safety profile made it the first peptide to achieve mainstream clinical adoption for obesity.
Tirzepatide: Dual Agonism Raises the Bar
Tirzepatide (Mounjaro, Zepbound) targets both GLP-1R and GIPR — the glucose-dependent insulinotropic polypeptide receptor. This dual agonism produces synergistic effects on appetite suppression and metabolic rate. In the SURMOUNT-1 trial, participants on 15mg weekly tirzepatide lost an average of 20.9% of body weight over 72 weeks. The addition of GIP receptor activity appears to enhance the hypothalamic satiety signaling beyond what GLP-1 alone achieves.
Retatrutide: Triple Agonism and the Next Frontier
Retatrutide adds glucagon receptor (GCGR) agonism to the GLP-1R and GIPR targets of tirzepatide. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation, adding a thermogenic component to the appetite-suppressing effects of the other two targets. Phase 2 trials showed up to 24.2% weight loss over 48 weeks — the highest efficacy of any peptide in this class to date. Retatrutide is currently in Phase 3 trials.
AOD-9604: Targeted Lipolysis
AOD-9604 is a modified fragment of human growth hormone (hGH176-191) that retains the lipolytic (fat-burning) properties of growth hormone without the anabolic or IGF-1-stimulating effects. It works by activating β3-adrenergic receptors on adipocytes, stimulating direct fat cell breakdown. Unlike GLP-1 agonists, AOD-9604 does not affect appetite — it acts directly on adipose tissue. Research suggests it may be particularly effective for stubborn subcutaneous fat when combined with GLP-1 class peptides.
5-Amino-1MQ: The NNMT Inhibitor
5-Amino-1-methylquinolinium (5-Amino-1MQ) represents a different mechanistic approach. Rather than acting on appetite or fat cell receptors, it inhibits nicotinamide N-methyltransferase (NNMT) — an enzyme that regulates adipocyte differentiation and metabolic rate. By inhibiting NNMT, 5-Amino-1MQ increases NAD+ availability in fat cells, upregulates SIRT1 activity, and shifts adipocytes toward a metabolically active 'beige' phenotype. Early research suggests significant reductions in fat mass without changes in lean body mass.
Stacking Considerations
The most effective research protocols for metabolic optimization typically combine a GLP-1 class peptide (for appetite regulation) with a direct lipolytic agent (AOD-9604 or 5-Amino-1MQ). This multi-target approach addresses both the caloric intake side and the fat oxidation side of the energy equation. See the CFPS Research Protocol Database for specific stacking protocols, dosing schedules, and cycle lengths.